No products in the cart.
India’s Production-Linked Scheme Will Enhance Domestic Bulk Drug Manufacturing Capabilities
Key View
- India’s production-linked incentive scheme will reduce imports by promoting domestic manufacturing of pharmaceuticals.
- The country will remain keen to secure its drugs market from external shocks, lessen import dependencies, and continue support for the domestic production capabilities in APIs.
- Reducing India’s dependence on Mainland China will not be easy to achieve.
India’s production-linked incentive (PLI) scheme will reduce import by promoting domestic manufacturing of pharmaceuticals. The Indian government approved a production-linked incentive (PLI) scheme in February 2021 targeting India’s pharmaceutical sector for enhancing drug manufacturing capabilities and expanding exports. The key objectives of the scheme are:
Related Posts
Mongolia-Russia Relations Likely To Strengthen As Gas Pipeline Gains Momentum
Key View At Fitch Solutions, we believe that diplomatic relations between Mongolia and Russia will continue strengthening, propelled further...
Bank Of Thailand On The Cusp Of Tightening Monetary Policy
Key View We expect the Bank of Thailand to hike its policy rate by 50bps to 1.00% by end-2022,...
Asia Autos: ‘Zero-Covid’ Policy Dragging Regional Vehicle Sales Into A Contraction For 2022
Key View While markets in South East Asia (SEA) will perform well in 2022, some of the region's biggest...
